Once-daily indacaterol 75 µg in moderate-to-severe COPD: results of a Phase IV study assessing time until patients’ perceived onset of effect

This article was published in the following Dove Press journal: International Journal of COPD
1 September 2014
Number of times this article has been viewed

Background: Indacaterol 75 µg once daily is a long-acting β₂ agonist approved for maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). The purpose of this study was to evaluate patients’ perception of onset of effect with a single dose.

Methods: In this double-blind, crossover, Phase IV study, 40 patients were randomized to receive a single dose of indacaterol 75 µg or placebo via a dry powder inhaler device. The primary variable was time until patient’s perception of onset of effect, using a simple self-administered (nonvalidated) questionnaire that patients answered at nine protocol-specified time points. Exploratory variables included change in forced expiratory volume in 1 second (FEV₁) and change in percent predicted FEV₁ from predose to postdose (determined 60–75 minutes postdose).

Results: The least-squares mean time to patient’s perception of onset of effect was 25.4 minutes and 23.9 minutes for indacaterol and placebo, respectively. There was no significant effect for treatment, period, or sequence on the time to patient’s perception. In addition, no statistically significant differences between treatments were observed for patient’s global satisfaction with onset of effect and global expectation of treatment adherence. For the exploratory variable change in FEV₁ from predose to postdose, indacaterol showed superiority over placebo with a clinically relevant least-squares mean treatment difference of 0.12 L (P<0.0001). There was little or no association between patient’s perception of time to onset of effect and change in FEV₁, or change in percent predicted FEV₁. Both treatments were well tolerated.

Conclusion: A single dose of indacaterol 75 µg did not separate from placebo in terms of patient perception of onset, although there was an improvement in FEV₁ for indacaterol compared with placebo. Development and use of a validated questionnaire may be needed to address the inconsistency in evaluating this patient-related outcome.

Keywords: bronchodilator, long-acting, perceived onset of action, single dose

Introduction

Indacaterol 75 µg once daily has been demonstrated to be an effective maintenance bronchodilator treatment for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) in two 12-week Phase III studies. These studies demonstrated a rapid onset of effect (90–100 mL difference from placebo in forced expiratory volume in 1 second [FEV₁] at 5 minutes postdose on day 1) and sustained 24-hour bronchodilation over 12 weeks, along with significant improvements versus placebo in dyspnea and health status, and reduced rescue medication use.¹,²
Although FEV$_1$ is a standardized and accepted measurement of airflow limitation, it does not assess the impact of lung function improvement in patients.\textsuperscript{3–5} Patient-reported outcome (PRO) measures that assess changes in a patient’s health status (including the St George’s Respiratory Questionnaire\textsuperscript{6} [SGRQ] and COPD Assessment Test\textsuperscript{7}) or degree of dyspnea (including the Baseline/Transition Dyspnea Indexes\textsuperscript{8} and Medical Research Council score\textsuperscript{9}) are considered increasingly pertinent to evaluating the impact of COPD on patients and the long-term management of the disease.\textsuperscript{3–5}

In addition to these validated PRO measures, there is also an interest in PRO measures that assess the impact of bronchodilator treatment with respect to patient perception of onset and satisfaction with onset of effect in patients with COPD. Bronchodilator treatments in COPD have demonstrated an acute improvement in spirometric indices,\textsuperscript{10} and there is a potential for patient perception of onset of effect to improve adherence to treatment. Although patient-reported assessment of time until the perception of onset of effect based on a questionnaire has been described in asthma and COPD,\textsuperscript{11,12} overall there is limited information on this topic in the published literature.

This randomized, double-blind, placebo-controlled, crossover, single-dose, Phase IV study assessed the perception of onset of action in patients with moderate-to-severe COPD when treated with a single dose of indacaterol 75 µg or placebo, using a simple patient-reported instrument to detect perception of onset of effect.

**Methods**

**Study design**

This was a randomized, double-blind, placebo-controlled, single-dose, crossover, Phase IV study conducted in six centers in the US. Signed approvals for the study were obtained from a central Institutional Review Board (Copernicus Group Independent Review Board).

**Patients**

This study recruited patients with moderate-to-severe COPD (defined according to the Global Initiative for Chronic Obstructive Lung Disease [GOLD] 2009 criteria),\textsuperscript{13} aged ≥40 years, and with a smoking history of ≥10 pack-years. Their FEV$_1$ was to be ≤70% and ≥40% of predicted and FEV$_1$/forced vital capacity <70% at screening, both measured postbronchodilator (albuterol 90 µg × four puffs). Patients were also required to have breathing symptoms that interfered with some daily activities, as determined by the investigators. Patients gave their written informed consent. Patients were excluded if they had a history of asthma or repeated COPD exacerbations (two or more in the previous 2 years). Medication-based exclusions included bronchodilators for COPD with a pharmacodynamic activity greater than 48 hours and/or once-daily dosing, and a washout of 48 hours was required for patients on maintenance bronchodilators (eg, formoterol and salmeterol).

**Treatments**

At visit two (3–10 days postscreening), eligible patients were randomized in a crossover design in a 1:1 ratio to receive a single dose of indacaterol 75 µg followed by placebo at visit three, or placebo at visit two followed by indacaterol 75 µg at visit three (washout of 7–10 days between visits), via a dry powder inhaler device. Patients receiving inhaled corticosteroids at baseline continued this treatment (or the inhaled corticosteroids component alone if taken as a fixed combination with a bronchodilator) at equivalent dose and regimen during the study. Albuterol was available for rescue use. Patients were instructed to withhold albuterol within 6 hours of visit two and visit three and to keep their albuterol with them as rescue medication at all times, including the 6-hour period prior to visits two and three.

**Assessments**

The primary variable was time (in minutes) to patient’s perception of onset of effect, defined as the first time point (5 minutes, 7.5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, and 60 minutes postdose) that the patient responded “yes” to the self-administered statement “I feel that the drug is working in improving my breathing.” This tool was chosen because it was used to assess perceptions of onset of action in a previous study of patients with COPD,\textsuperscript{11} and a validated instrument was not available for this purpose. Exploratory variables included change in FEV$_1$ and change in percent predicted FEV$_1$ from predose to postdose (60–75 minutes postdose), as well as patient’s global satisfaction with onset of effect and patient’s expectation of treatment adherence (both administered after completion of the 60 minute perception of onset of effect questionnaire; Table 1).

Safety assessments included all adverse events (AEs), serious AEs, vital signs, blood chemistry, urine tests, and electrocardiograms.

**Randomization**

Patients were randomized to one of the two treatment sequences in this double-blind study (see Treatment section). At visit 2, eligible patients were given the lowest available...
Table 1 Patient’s global satisfaction with the onset of effect and patient’s expectation of treatment adherence

<table>
<thead>
<tr>
<th>Patient’s global satisfaction with the onset of effecta</th>
<th>Patient’s expectation of treatment adherencea</th>
</tr>
</thead>
<tbody>
<tr>
<td>“I am satisfied with how quickly the study medication began working on my breathing.”</td>
<td>“I would be more likely to take my medication once every day if it worked on my breathing as fast as this medication.”</td>
</tr>
<tr>
<td>1: strongly agree</td>
<td>1: strongly agree</td>
</tr>
<tr>
<td>2: somewhat agree</td>
<td>2: somewhat agree</td>
</tr>
<tr>
<td>3: neither agree nor disagree</td>
<td>3: neither agree nor disagree</td>
</tr>
<tr>
<td>4: somewhat disagree</td>
<td>4: somewhat disagree</td>
</tr>
<tr>
<td>5: strongly disagree</td>
<td>5: strongly disagree</td>
</tr>
</tbody>
</table>

Note: *Patients reported whether they agreed or disagreed with the statement using a five-point scale (ranging from 1: strongly agree to 5: strongly disagree).*

The full analysis set (FAS) consisted of all patients to whom the study drug had been assigned through randomization. Patients in the FAS were analyzed according to the treatment sequence to which they were assigned. The safety set consisted of all patients who received at least one dose of either study drug. Patients in the safety set were analyzed according to the treatment they received.

The primary variable was analyzed for the FAS using a repeated-measures analysis of variance model with fixed effects for treatment, period, and sequence and a random effect for patients within sequence. Patients who did not perceive onset of effect by 60 minutes were considered as having a perceived onset of effect at 70 minutes. For analysis of the primary variable, if a patient had missing data for the second period, no imputations were performed.

The change in FEV₁ from predose to postdose, the patients’ global satisfaction with the onset of effect, and patients’ expectation of treatment adherence were also analyzed for the FAS with the same repeated-measures analysis of variance model that was used for the analysis of the primary variable.

The associations between time until patient’s perception of onset of effect, and change in percent predicted FEV₁ from predose to postdose were examined by computing Pearson’s correlation coefficients and Spearman’s rank correlation coefficients. The association between patient’s global satisfaction with onset of effect and patient’s expectation of treatment adherence was examined by computing Spearman’s rank correlation coefficient.

All statistical tests were conducted against a two-sided alternative hypothesis and evaluated at a significance level of 0.05. All statistical analyses were performed using SAS®, Version 9.1.3 (SAS Institute, Inc., Cary, NC, USA).

Sample size calculation

The sample size was calculated based on the primary variable, time (in minutes) until patient’s perception of onset of effect. By assuming a within-patient correlation of 0.50, a between-patient standard deviation of 14, a significance level of 0.05, and a power of 87% to detect a difference of 7.5 minutes between the true means using a paired t-test, it was calculated that 36 patients were needed for randomization.¹⁴ Allowing for 10% of patients who may not complete both treatment periods, it was estimated that approximately 40 patients would need to be randomized to the two treatment sequences.

Results

Patients

Forty patients were randomized, with 20 patients in the indacaterol/placebo (IP) sequence and 20 patients in the placebo/indacaterol (PI) sequence. The FAS and safety set also included 20 patients each in the IP and PI sequences. The demographic data of patients are presented in Table 2.

Table 2 Demographics of the patient population (full analysis set) (means [standard deviations] are reported, unless otherwise stated)

<table>
<thead>
<tr>
<th></th>
<th>Indacaterol/ placebo (n=20)</th>
<th>Placebo/ indacaterol (n=20)</th>
<th>Overall (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>62.2 (10.29)</td>
<td>60.8 (6.90)</td>
<td>61.5 (8.68)</td>
</tr>
<tr>
<td>Male/female, %</td>
<td>55/45</td>
<td>80/20</td>
<td>68/32</td>
</tr>
<tr>
<td>Race, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>90.0</td>
<td>90.0</td>
<td>90.0</td>
</tr>
<tr>
<td>Black</td>
<td>10.0</td>
<td>0</td>
<td>5.0</td>
</tr>
<tr>
<td>Native American</td>
<td>0</td>
<td>5.0</td>
<td>2.5</td>
</tr>
<tr>
<td>Others</td>
<td>0</td>
<td>5.0</td>
<td>2.5</td>
</tr>
<tr>
<td>Ex-smoker/smoker, %</td>
<td>50/50</td>
<td>30/70</td>
<td>40/60</td>
</tr>
<tr>
<td>Years since chronic obstructive pulmonary disease diagnosis</td>
<td>7.7 (5.84)</td>
<td>9.4 (10.58)</td>
<td>8.5 (8.48)</td>
</tr>
</tbody>
</table>
Most patients were Caucasian (90.0%), male (67.5%), and current smokers (60.0%). The mean age was 61.5 years and the mean time since diagnosis of COPD was 8.5 years.

**Primary and exploratory variables**

For patients receiving indacaterol and placebo, the least-squares (LS) mean time until patient’s perception of onset of effect was 25.4 minutes and 23.9 minutes, respectively (Table 3). The LS mean of the IP difference was 1.5 minutes (P=0.75). The period effect (P=0.63) and sequence effect (P=0.82) were not statistically significant. The cumulative frequencies for time to patient’s perception of onset of effect are summarized in Table 4 and Figure 1. The mean values for onset of effect in the combined sequences for indacaterol and placebo were 25.58 minutes and 23.88 minutes, respectively.

For the exploratory variable change in FEV\textsubscript{1} from predose to postdose, indacaterol showed superiority over placebo with an LS mean treatment difference of 0.12 L (P<0.0001; Table 3). The mean (SD) predose FEV\textsubscript{1} (L) of first dose for indacaterol and placebo was 1.53 (0.606) and 1.59 (0.530), respectively. The improvement in FEV\textsubscript{1} with indacaterol 75 μg from predose to postdose was considered to be clinically relevant.\(^1\) The magnitudes of the Pearson’s and Spearman’s correlation coefficients (for combined treatments and combined sequences) indicated little or no association between patient’s perception of time until onset of effect and change in FEV\textsubscript{1}, and between patient’s perception of time until onset of effect and change in percent predicted FEV\textsubscript{1} (correlation coefficients ranging from −0.06 to 0).

The Spearman’s correlation coefficients (for combined treatments and combined sequences) for examining the association between patient’s global satisfaction with onset of effect and patient’s expectation of treatment adherence (60 minutes postdose) ranged from 0.65 to 0.96, indicating a moderate to strong positive association between these two variables. For patient’s global satisfaction with onset of effect, there was a small improvement with indacaterol compared with placebo (LS mean 2.2 vs 2.5; difference −0.2), but this was not statistically different (P=0.40; Table 3). Similarly, for patient’s expectation of treatment adherence score, the LS mean treatment difference (−0.2) between indacaterol (2.1) and placebo (2.3) indicated a small improvement but was not significant (P=0.54; Table 3).

**Safety**

Overall, five patients (12.5%) receiving indacaterol and one patient (2.5%) receiving placebo experienced at least one AE after study treatment. Cough was the most frequently occurring AE, reported by two patients (5.0%) receiving indacaterol and no patients receiving placebo. Other AEs reported by patients in the indacaterol group included rhinorrhea, throat irritation, dyspepsia, pyrexia, muscle spasm, and headache (one case per AE [2.5%]). COPD worsening was reported by one patient in the placebo group. One patient in the placebo group discontinued due to AEs. No serious AEs or deaths were reported in the study.

**Discussion**

In this Phase IV, single-dose study, the effect of active treatment (indacaterol 75 μg once daily) and placebo on patient’s perception of onset of effect was evaluated with a simple patient-reported instrument in patients with moderate-to-severe COPD. The study did not show a significant treatment, period, or sequence effect for the primary variable, time until patient’s perception of onset of effect. However, a statistically significant improvement was observed in FEV\textsubscript{1} with indacaterol compared with placebo (Table 3). The treatment difference of 0.12 L (P<0.0001) in FEV\textsubscript{1} at 60–75 minutes postdose for indacaterol versus placebo was clinically meaningful\(^7\) and

**Table 3** Primary and exploratory variables during treatment with indacaterol and placebo in the full analysis set (treatment sequences combined)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Indacaterol (n=40), LS mean (SE)</th>
<th>Placebo (n=40), LS mean (SE)</th>
<th>Indacaterol–placebo difference, LS mean (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to patient’s perception of onset of effect, minutes</td>
<td>25.4 (4.39)</td>
<td>23.9 (4.34)</td>
<td>1.5 (−8.1, 11.1)</td>
<td>0.75</td>
</tr>
<tr>
<td>Change in FEV\textsubscript{1} from predose to postdose, L</td>
<td>0.09 (0.019)</td>
<td>−0.03 (0.019)</td>
<td>0.12 (0.08, 0.15)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Patient’s global satisfaction with onset of effect</td>
<td>2.2 (0.21)</td>
<td>2.5 (0.21)</td>
<td>−0.2 (−0.8, 0.3)</td>
<td>0.40</td>
</tr>
<tr>
<td>Patient’s expectation of treatment adherence</td>
<td>2.1 (0.21)</td>
<td>2.3 (0.21)</td>
<td>−0.2 (−0.7, 0.4)</td>
<td>0.54</td>
</tr>
</tbody>
</table>

**Abbreviations:** CI, confidence interval; FEV\textsubscript{1}, forced expiratory volume in 1 second; LS, least squares; SE, standard error.
was comparable with the improvement reported in trough 
FEV₁ with indacaterol 75 µg versus placebo by Kerwin et al.²
Therefore, the absence of patient perception of onset of effect 
ocurred despite a strong bronchodilator response.

Evaluation of patient perceptions of treatment effects 
involve significant challenges. In particular, it is recognized 
that subjective responses to placebo may be similar to those 
reported for active treatments, despite marked differences in 
objective measures. For example, Wechsler et al.² compared 
the effects of the bronchodilator albuterol with two placebo 
treatments and no intervention in patients with asthma. 
Although albuterol significantly improved FEV₁, whereas the 
placebo interventions did not, self-reported outcomes were 
similar between the active and placebo groups. Wechsler 
et al.² concluded that placebo treatments can result in clinically 
meaningful effects that may rival those of active treatments in 
patients with asthma. Other studies have also indicated that 
placebo exerts positive effects on subjectively assessed outcomes 
(such as pain and depression) but not on objectively evaluated 
outcomes.² In 610 patients with asthma, Wise et al.² demonstrated 
that placebo given with enhanced messages to increase 
the expectation of benefit significantly increased subjective 
outcomes but had no effect on objective outcomes. The results 
of our study are consistent with these findings.

Disparities between subjective and objective assessments 
have been noted in other trials of COPD treatments. 
For example, significant improvements (P<0.05) in FEV₁ 
and health status (SGRQ) were noted at week 12 in patients 
receiving indacaterol 75 µg, compared with placebo, in 
two pivotal Phase III studies.² In both the studies, the

---

**Table 4** Cumulative frequencies for time until patient’s perception of onset of effect by sequence and treatment (full analysis set)

<table>
<thead>
<tr>
<th>Time to perceived onset of effect</th>
<th>Indacaterol/placebo (n=20)</th>
<th>Placebo/indacaterol (n=20a)</th>
<th>Overall (n=40a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 minutes, n (%)</td>
<td>8 (40.0)</td>
<td>7 (36.8)</td>
<td>15 (38.5)</td>
</tr>
<tr>
<td>7.5 minutes</td>
<td>9 (45.0)</td>
<td>9 (47.4)</td>
<td>18 (46.2)</td>
</tr>
<tr>
<td>10 minutes</td>
<td>11 (55.0)</td>
<td>12 (63.2)</td>
<td>23 (59.0)</td>
</tr>
<tr>
<td>15 minutes</td>
<td>14 (70.0)</td>
<td>13 (68.4)</td>
<td>27 (69.2)</td>
</tr>
<tr>
<td>20 minutes</td>
<td>14 (70.0)</td>
<td>13 (68.4)</td>
<td>27 (69.2)</td>
</tr>
<tr>
<td>30 minutes</td>
<td>14 (70.0)</td>
<td>13 (68.4)</td>
<td>27 (69.2)</td>
</tr>
<tr>
<td>40 minutes</td>
<td>15 (75.0)</td>
<td>13 (68.4)</td>
<td>28 (71.8)</td>
</tr>
<tr>
<td>50 minutes</td>
<td>15 (75.0)</td>
<td>14 (73.7)</td>
<td>29 (74.4)</td>
</tr>
<tr>
<td>60 minutes</td>
<td>15 (75.0)</td>
<td>14 (73.7)</td>
<td>29 (74.4)</td>
</tr>
<tr>
<td>&gt;60 minutes</td>
<td>20 (100)</td>
<td>19 (100)</td>
<td>39 (100)</td>
</tr>
</tbody>
</table>

Mean (SD) indacaterol by sequence, minutes 25.13 (27.73) 26.05 (28.79) 25.58 (27.88)
Median indacaterol (IQR) by sequence, minutes 10.00 (50.00) 10.00 (65.00) 10.00 (65.00)

Placebo, n (%) 5 minutes 8 (40.0) 8 (40.0) 16 (40.0) 7.5 minutes 9 (45.0) 11 (55.0) 20 (50.0) 10 minutes 10 (50.0) 12 (60.0) 22 (55.0) 15 minutes 12 (60.0) 15 (75.0) 27 (67.5) 20 minutes 14 (70.0) 15 (75.0) 29 (72.5) 30 minutes 14 (70.0) 15 (75.0) 29 (72.5) 40 minutes 15 (75.0) 16 (80.0) 31 (77.5) 50 minutes 15 (75.0) 16 (80.0) 31 (77.5) 60 minutes 15 (75.0) 16 (80.0) 31 (77.5) >60 minutes 20 (100) 20 (100) 40 (100)

Mean (SD) placebo by sequence, minutes 25.88 (27.45) 21.88 (25.93) 23.88 (26.43) Median placebo (IQR) by sequence, minutes 12.50 (50.00) 7.50 (22.50) 8.75 (35.00)

**Notes:** Indacaterol data missing for one patient due to premature study discontinuation; a for patients who did not perceive onset of effect by 60 minutes, time to perceived onset was taken as equal to 70 minutes in subsequent computations.

**Abbreviations:** IQR, interquartile range; SD, standard deviation.

---

**Figure 1** Cumulative distribution functions for time to patient’s perception of onset of effect by treatment.
improvements in FEV\textsubscript{1} met the prespecified criterion for clinical relevance (120 mL difference versus placebo), and the differences in the SGRQ scores approached clinical significance (defined as a four-point difference versus placebo).\textsuperscript{2,4} However, dyspnea (measured using the Transition Dyspnea Index) was significantly improved with indacaterol 75 µg versus placebo in one study but not in the other.\textsuperscript{1} Disparities between different assessments were also observed in a study by Lindberg et al\textsuperscript{11} that used the same instrument employed in our study to evaluate budesonide/formoterol, salmeterol/fluticasone, salbutamol, and placebo in patients with COPD. In this trial, significant objective differences were recorded in lung function between active treatments, but patient perceptions of the onset of action were similar. Of note, 61% of placebo recipients answered “yes” when asked whether their medication was working (versus 81%-84% for the active treatments). As well as raising concerns regarding the sensitivity of the questionnaire, Lindberg et al\textsuperscript{11} noted that patients may have been in a “steady state” with regard to symptoms, and many may have been relatively asymptomatic, thus compromising the ability of the instrument to assess treatment effects.

Studies investigating the effect of single-dose bronchodilators on lung function, exercise capacity, and walking performance in patients with COPD have reported improvements in objective measures (lung function, walking performance, and arterial oxygen saturation), as well as subjective measures (perceived breathlessness, exertion, chest pain, and fatigue).\textsuperscript{19-21} In contrast to the current study, where there was no physical challenge prior to the assessments, these earlier trials involved an exercise test. It can be hypothesized that an improvement in subjective assessments could have been seen with indacaterol if the study included a physical challenge, such as a 6-minute walk test.

We assessed the single-dose effect of indacaterol 75 µg (US approved dose) versus placebo on patient perception of onset of effect. The sensitivity of the instrument used in this study and the symptom severity of the patients enrolled may have influenced the results. An effect on patient perception of onset of effect with indacaterol may have been observed with a different instrument with a higher sensitivity, or had the study been conducted among patients with more severe impairment (eg, with severe to very severe air flow obstruction or with acute symptoms such as dyspnea or fatigue as a result of exercise). Patients with COPD may need the use of rescue medication for immediate relief of bronchospasm. Our study allowed the use of albuterol as a rescue medication for rapid relief of acute dyspnea.

**Conclusion**

In summary, a single dose of indacaterol 75 µg was not associated with a significant difference in patient perception of benefit compared with placebo, despite significant improvement in FEV\textsubscript{1}. There were no differences in time to perception of onset of effect between indacaterol and placebo. It may be that a more sensitive instrument or an exercise challenge study would be required to address the discrepancy between a patient’s perception of effect and the significant bronchodilation achieved. As has been shown in other studies, significant improvements in physiologic function do not always correlate directly with patients’ perception of relief.

**Acknowledgments**

The authors thank the patients and staff at the participating study centers and David Young (Novartis, Horsham, UK) for critically reviewing the manuscript. The study was funded by Novartis Pharmaceuticals Corporation (East Hanover, NJ, USA); Anneliese LaRose was the clinical trial lead. Melanie Stephens, a professional medical writer (CircleScience, London, UK) funded by Novartis Pharmaceuticals Corporation, assisted in the preparation of the manuscript.

**Disclosure**

Thomas M Siler has received research support from Arena, Boehringer Ingelheim, Daiichi Sankyo, Dey Laboratories, Forest Research Institute, Genentech, GlaxoSmithKline, Johnson and Johnson, Merck, Novartis, Pfizer Therapeutics, Schering, and Sunovion, and has received honoraria from AstraZeneca, Boehringer Ingelheim, Forest, Novartis, and UCB. Craig F LaForce is a consultant to Novartis and has received honoraria from Merck and Co. He is the principal investigator on trials with the following pharmaceutical companies: Array, Boehringer Ingelheim, GlaxoSmithKline, Merck Research Laboratories, Novartis, Pfizer, Roxane Laboratories, Teva, Sunovion, and Watson Pharmaceuticals. Selwyn Spangenthal has received honoraria from AstraZeneca, Forest, Mylan Labs, and Novartis. Farid Kianifard and James Williams are employees of Novartis Pharmaceuticals.

**References**


